PMC6271067 Seiwerth, S., et al
M., Lima, S
However, because the initial dose is low, some patients may notice the appetite suppression is strongest for the first four days and slightly wanes as they approach their next scheduled injection
If the pain persists for more than a week or becomes severe, it is important to consult with your healthcare provider to rule out other causes
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, citing no clinical need for large-scale compounding now that FDA-approved supply is stable
For those struggling with weight loss and who meet the FDA-approved criteria, Semaglutide GLP-1 can be a valuable option